Ann: First Patient Treated in Phase 2 GvHD Trial, page-54

Stratching credibility there Pledge? You complain of being 'besmirched' but then in the same breath say "he's a half-wit (as opposed to belcher being a f-wit)". You've demonstrably got stuff wrong on the CYP releases or evidently did not read them. You (and another regular MSB poster) often pepper CYP releases immediately with FUD on unrelated cash burn (which is a natural weakness for any pre-commercial bio-tech) without giving a financial analysis based explanation as to your aggressively stated opinion. Others come back patiently to correct with evidence, as @pfeifer1982 did today on your suggestion of some sort of deception on US sites, and then your argument switches to the bizarre crime of MSB not naming the specific venue on one patient?

Naming the venue would break basic trial protocols Pledge? Its a randomized placebo-controlled trial Pledge? Where does it stop? Should they name the 2nd, 3rd....39th venue patient as well?

Play nicely and others will play nicely with you as I have on your MSB thread today - like you, I have little esteem for Silviu and am delighted to see the back of Ross at CYP.